Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View

Dr. Christin Collins

Breast Surgical Onc · MetroHealth

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Society of Surgical Oncology Breast Disease Site Working Group Statement on Bilateral Risk-Reducing Mastectomy: Indications, Outcomes, and Risks.

    Nov 13, 2024DOI: 10.1245/s10434-024-16484-2Journal ArticleASO

    Written by: Puneet SinghDoreen M AgneseMiral AminAndrea V BarrioAstrid Botty van den BrueleErin E BurkeDavid N DanforthFrederick M DirbasFiras EladoumikdachiOluwadamilola M FayanjuOlga KantorShicha KumarMarie Catherine LeeCindy MatsenToan T NguyenTolga OzmenKo Un ParkJennifer K PlichtaChantal ReynaShayna L ShowalterToncred StybloNicholas TranakasAnna WeissAshley WoodfinChristine LarongaJudy C Boughey

    Find these authors on Roon

    JP

    Dr. Jennifer Plichta

    Breast Surgical Onc · Duke University

    CR

    Dr. Chantal Reyna

    Breast Surgical Onc · Foster G. McGaw Hospital

    Summary

    Bilateral risk-reducing mastectomy (BRRM) is the surgical removal of both breasts to reduce the risk of cancer. In this Society of Surgical Oncology position statement, we review the literature addressing the indications, outcomes, and risks of BRRM to update the society's 2017 statement. We held a virtual meeting to outline key topics and conducted a literature search using PubMed to identify relevant articles. After literature review, recommendations were made according to group consensus. Individuals with a high lifetime risk of breast cancer due to pathogenic variants in high penetrance breast cancer-predisposition genes, early chest or breast radiation exposure, or a compelling family history should be counseled on the option of BRRM. However, BRRM is not recommended for most patients with high-risk lesions and may be contraindicated in patients who have other competing cancers and/or a high risk of surgical complications. BRRM effectively reduces the risk of breast cancer development, although the survival benefit is unclear. For patients with low-to-moderate breast cancer risk, alternative management strategies should be encouraged, including lifestyle modifications, high-risk screening, and risk-reducing medications. Discussions of BRRM should cover: (1) breast-cancer risk estimates; (2) the procedure's degree of risk reduction and impact on survival; (3) surgical techniques, potential surgical complications and long-term sequelae; and (4) alternatives to surgery. Surgeons should encourage shared and informed decision making with patients who have an elevated lifetime risk of developing breast cancer.
    CRDr. Chantal Reyna

    Dr. Chantal Reyna

    Surgery · Breast Surgical Oncology
    Loyola University Medical Center
    chantal